路勁黃竹坑站新盤「晉環」料本周開價
路勁地產銷售及市場推廣總監封海倫在記者會上表示,公司與港鐵(00066.HK)合作的黃竹坑站「港島南岸」第一期項目「晉環」已上載樓書,預期本周向公眾開放示範單位及公布單價,料於5月初展開首輪銷售。
她指,項目反應熱烈,公布樓書後三房已接獲逾3,000個查詢。而首輪推售單位涉最少160伙,主打兩房及三房,四房單位則估計會以招標形式銷售。由於項目為港島區三十年以來首個鐵路上蓋新盤,未必有類似項目比較,但項目定價會參考南區豪宅。
她提到,項目共有800伙,主打房型的三房實用面積介乎639至937平方呎,共涉222伙,佔項目單位30%。至於四房單位面積介乎965至1,302平方呎,涉58伙,佔項目僅7%。(ek/u) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.